A detailed history of Gofen & Glossberg LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Gofen & Glossberg LLC holds 2,970 shares of VRTX stock, worth $1.37 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
2,970
Previous 2,896 2.56%
Holding current value
$1.37 Million
Previous $839,000 2.26%
% of portfolio
0.02%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Jan 13, 2023

BUY
$285.76 - $321.48 $21,146 - $23,789
74 Added 2.56%
2,970 $858,000
Q3 2022

Oct 13, 2022

BUY
$273.83 - $305.53 $2,190 - $2,444
8 Added 0.28%
2,896 $839,000
Q2 2022

Jul 14, 2022

SELL
$234.96 - $292.55 $48,401 - $60,265
-206 Reduced 6.66%
2,888 $814,000
Q4 2021

Jan 25, 2022

SELL
$177.01 - $223.45 $5,487 - $6,926
-31 Reduced 0.99%
3,094 $679,000
Q3 2021

Oct 13, 2021

BUY
$181.39 - $202.99 $5,623 - $6,292
31 Added 1.0%
3,125 $567,000
Q2 2021

Jul 13, 2021

SELL
$187.49 - $221.1 $61,121 - $72,078
-326 Reduced 9.53%
3,094 $624,000
Q1 2021

Apr 13, 2021

SELL
$207.02 - $241.31 $7,245 - $8,445
-35 Reduced 1.01%
3,420 $735,000
Q4 2020

Jan 15, 2021

SELL
$207.01 - $276.09 $8,694 - $11,595
-42 Reduced 1.2%
3,455 $817,000
Q3 2020

Oct 09, 2020

BUY
$255.65 - $303.1 $52,663 - $62,438
206 Added 6.26%
3,497 $952,000
Q1 2020

Apr 14, 2020

BUY
$199.77 - $247.81 $2,597 - $3,221
13 Added 0.4%
3,291 $783,000
Q4 2019

Jan 28, 2020

SELL
$166.71 - $223.91 $12,336 - $16,569
-74 Reduced 2.21%
3,278 $718,000
Q3 2019

Oct 10, 2019

BUY
$166.23 - $187.09 $6,981 - $7,857
42 Added 1.27%
3,352 $568,000
Q2 2017

Aug 16, 2017

BUY
N/A
3,310
3,310 $427,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Gofen & Glossberg LLC Portfolio

Follow Gofen & Glossberg LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gofen & Glossberg LLC , based on Form 13F filings with the SEC.

News

Stay updated on Gofen & Glossberg LLC with notifications on news.